BLA 761342 · Janssen Biotech
Talvey
Talquetamab-Tgvs · Injection
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanCDER novel approval, Aug 9, 2023: To treat adults with relapsed or refractory multiple myeloma who have received at least four prior therapies
Last checked: Nov 20, 2026Latest source record: May 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Aug 9, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
39
7 Phase 3, 20 recruiting
FAERS reports
1,489
924 serious, 114 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITY, including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Cytokine release syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving TALVEY. Initiate TALVEY treatment with step-up dosing to reduce the risk of CRS. Withhold TALVEY until CRS resolves or permanently discontinue based on severity [see Dosage and Administration (2.2 , 2.5 ) , Warnings and Precautions (5.1) ] . Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS), and serious and life threatening or fatal reactions, can occur with TALVEY. Monitor patients for signs and symptoms of neurologic toxicity including ICANS during treatment and treat promptly. Withhold or permanently discontinue TALVEY based on severity [see Dosage and Administration (2.5) , Warnings and Precautions (5.2) ]...
What it is approved for
From the label in effect Oct 8, 2025.
TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). TALVEY is a bispecific GPRC5D-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 )
Mechanism: Talquetamab-tgvs is a bispecific T-cell engaging antibody that binds to the CD3 receptor expressed on the surface of T-cells and G protein-coupled receptor class C group 5 member D (GPRC5D) expressed on the surface of multiple myeloma cells and non-malignant plasma cells, as well as healthy tissues such as epithelial cells in keratinized tissues of the skin and tongue. In vitro, talquetamab-tgvs activated T-cells caused the release of proinflammatory cytokines and resulted in the lysis of multiple myeloma cells. Talquetamab-tgvs had anti-tumor activity in mouse models of multiple myeloma.
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 9, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
2 products under this application
- TALVEY · TALQUETAMAB-TGVS 40MG/ML · INJECTABLE, INJECTION · Prescription
- TALVEY · TALQUETAMAB-TGVS 3MG/1.5ML(2MG/ML) · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Talquetamab" as an intervention, any sponsor and status, largest first.
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05552222 · 1,590 participants (planned) · Start Oct 25, 2022 · Primary completion Apr 30, 2031
Drug: Teclistamab; Daratumumab and 3 more · For: Multiple Myeloma
Sites: Gilbert, Arizona; Tucson, Arizona; Clovis, California · 270 sites in all
- Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness LevelPivotal-lookingRecruiting
University of LeedsAcademic, hospital or other
NCT07649525 · 1,226 participants (planned) · Start Jul 3, 2026 · Primary completion Jun 2033
Drug: Daratumumab; Lenalidomide and 3 more · For: Multiple Myeloma (MM); Plasma Cell Leukemia (PCL)
Sites: Bristol, United Kingdom; Eastbourne, United Kingdom; Leeds, United Kingdom · 5 sites in all
- Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple MyelomaPivotal-lookingNot yet recruiting
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT07887984 · 920 participants (planned) · Start Dec 23, 2026 · Primary completion Aug 1, 2033
Drug: Daratumumab and Recombinant Human Hyaluronidase; Lenalidomide and 5 more · For: Multiple Myeloma (MM)
- A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05455320 · 864 participants · Start Oct 13, 2022 · Primary completion Jul 30, 2027
Drug: Talquetamab; Daratumumab and 2 more · For: Multiple Myeloma
Sites: Tucson, Arizona; Little Rock, Arkansas; Norwalk, Connecticut · 216 sites in all
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomidePivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06208150 · 838 participants · Start Jan 22, 2024 · Primary completion Apr 1, 2026
Drug: Talquetamab; Pomalidomide and 4 more · For: Multiple Myeloma
Sites: Clovis, California; Santa Monica, California; New Haven, Connecticut · 242 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04634552 · 510 participants (planned) · Start Feb 1, 2021 · Primary completion Jun 30, 2027
Drug: Talquetamab · For: Hematological Malignancies
Sites: Birmingham, Alabama; Little Rock, Arkansas; Duarte, California · 78 sites in all
- BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.Pivotal-lookingNot yet recruiting
Anne Louise Tølbøll SørensenAcademic, hospital or other
NCT07474961 · 400 participants (planned) · Start Mar 2027 · Primary completion Dec 2036
Drug: teclistamab OR talquetamab OR elranatamab OR linvoseltamab; BTK inhibitors (ibrutinib and zanubrutinib) · For: Waldenstrom Macroglobulinaemia; Multiple Myeloma
Sites: Copenhagen, Denmark; Aalborg, Denmark; Aarhus, Denmark · 5 sites in all
CelgeneBristol Myers Squibb (BMY)
NCT03601078 · 312 participants · Start Dec 13, 2018 · Primary completion Jan 15, 2026
Drug: bb2121; Lenalomide and 1 more · For: Multiple Myeloma
Sites: Scottsdale, Arizona; San Francisco, California; Tampa, Florida · 25 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- cytokine release syndrome296
- ageusia140
- skin exfoliation126
- dysgeusia124
- weight decreased121
- dry mouth105
- immune effector cell-associated neurotoxicity syndrome102
- nail disorder95
- pyrexia93
- off label use89
- onychomadesis87
- taste disorder82
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2023 | 80 |
| 2024 | 326 |
| 2025 | 608 |
| 2026 | 475 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Talvey (Talquetamab-Tgvs)
2024 spending
$313K
Beneficiaries
n/a
11 claims
Per beneficiary
n/a
$8,856.00 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $312,905 |
Part B: Talvey (Talquetamab-Tgvs) · HCPCS J3055
2024 spending
$72.2M
Beneficiaries
692
4,344 claims
Per beneficiary
$104,377
2024 ASP limit $67.66 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $72,228,765 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma.
Cohen YC, Magen H, Gatt M, et al. · N Engl J Med 2025 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
Chari A, Minnema MC, Berdeja JG, et al. · N Engl J Med 2022 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study.
Chari A, Touzeau C, Schinke C, et al. · Lancet Haematol 2025 · Multicenter Study, Clinical Trial, Phase I
- Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.
Mina R, Beksac M, Rodríguez-Otero P, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab.
Kumar S, Mateos MV, Ye JC, et al. · N Engl J Med 2026 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Targeting GPRC5D With Talquetamab: A New Frontier in Bispecific Antibody Therapy for Relapsed/Refractory Multiple Myeloma.
Shaver J, Horton D, Halford Z · Ann Pharmacother 2025 · Systematic Review
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.